True Wealth Design LLC Purchases 510 Shares of Bruker Co. (NASDAQ:BRKR)

True Wealth Design LLC increased its position in Bruker Co. (NASDAQ:BRKR) by 4,636.4% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 521 shares of the medical research company’s stock after purchasing an additional 510 shares during the quarter. True Wealth Design LLC’s holdings in Bruker were worth $36,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of BRKR. First Horizon Advisors Inc. lifted its position in shares of Bruker by 120.4% in the second quarter. First Horizon Advisors Inc. now owns 399 shares of the medical research company’s stock valued at $25,000 after buying an additional 218 shares during the last quarter. UMB Bank n.a. lifted its holdings in Bruker by 115.3% during the 3rd quarter. UMB Bank n.a. now owns 661 shares of the medical research company’s stock valued at $46,000 after purchasing an additional 354 shares during the last quarter. Gordian Capital Singapore Pte Ltd bought a new position in Bruker during the second quarter worth $52,000. GAMMA Investing LLC increased its holdings in shares of Bruker by 81.0% in the third quarter. GAMMA Investing LLC now owns 867 shares of the medical research company’s stock valued at $60,000 after purchasing an additional 388 shares during the last quarter. Finally, Nisa Investment Advisors LLC raised its position in shares of Bruker by 20.0% in the second quarter. Nisa Investment Advisors LLC now owns 991 shares of the medical research company’s stock valued at $63,000 after purchasing an additional 165 shares during the period. 79.52% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Bruker

In other news, CEO Frank H. Laukien acquired 100,000 shares of the business’s stock in a transaction that occurred on Monday, November 18th. The shares were bought at an average price of $50.14 per share, with a total value of $5,014,000.00. Following the acquisition, the chief executive officer now directly owns 38,439,563 shares in the company, valued at $1,927,359,688.82. The trade was a 0.26 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Company insiders own 28.30% of the company’s stock.

Analysts Set New Price Targets

BRKR has been the topic of a number of research reports. Wolfe Research lowered shares of Bruker from an “outperform” rating to a “peer perform” rating in a research note on Monday, September 30th. TD Cowen decreased their target price on Bruker from $72.00 to $70.00 and set a “hold” rating on the stock in a research report on Wednesday, November 6th. Barclays dropped their price target on Bruker from $75.00 to $69.00 and set an “overweight” rating for the company in a report on Wednesday, November 6th. Wells Fargo & Company decreased their price objective on Bruker from $78.00 to $75.00 and set an “overweight” rating on the stock in a report on Wednesday, November 6th. Finally, Citigroup dropped their target price on Bruker from $80.00 to $75.00 and set a “buy” rating for the company in a report on Wednesday, November 6th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $79.36.

Bruker Stock Down 0.7 %

NASDAQ BRKR opened at $57.95 on Monday. Bruker Co. has a fifty-two week low of $48.07 and a fifty-two week high of $94.86. The business has a fifty day moving average price of $60.63 and a two-hundred day moving average price of $64.01. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.66 and a quick ratio of 0.73. The stock has a market capitalization of $8.79 billion, a PE ratio of 27.86, a PEG ratio of 3.89 and a beta of 1.20.

Bruker (NASDAQ:BRKR) last released its quarterly earnings data on Tuesday, November 5th. The medical research company reported $0.60 earnings per share for the quarter, missing the consensus estimate of $0.61 by ($0.01). The business had revenue of $864.40 million during the quarter, compared to analyst estimates of $866.46 million. Bruker had a net margin of 9.41% and a return on equity of 21.52%. The business’s quarterly revenue was up 16.4% compared to the same quarter last year. During the same period last year, the business earned $0.74 earnings per share. Equities analysts expect that Bruker Co. will post 2.4 earnings per share for the current fiscal year.

Bruker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 16th. Investors of record on Monday, December 2nd will be paid a $0.05 dividend. This represents a $0.20 annualized dividend and a yield of 0.35%. The ex-dividend date of this dividend is Monday, December 2nd. Bruker’s payout ratio is 9.62%.

Bruker Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.